917251-86-6 Usage
General Description
8-Bromo-3-(trifluoromethyl)quinoline is a chemical compound with the molecular formula C11H6BrF3N. It is a quinoline derivative that contains a bromine atom and a trifluoromethyl group attached to the quinoline ring. 8-Bromo-3-(trifluoromethyl)quinoline is commonly used as a building block in organic synthesis and pharmaceutical research. It has potential applications in the development of new drugs and bioactive molecules due to its unique structure and properties. The trifluoromethyl group can enhance the bioavailability and metabolic stability of drug molecules, making it a valuable chemical in medicinal chemistry. Additionally, the bromine atom can serve as a versatile functional group for further chemical modifications, making 8-Bromo-3-(trifluoromethyl)quinoline a versatile and valuable compound in chemical and pharmaceutical research.
Check Digit Verification of cas no
The CAS Registry Mumber 917251-86-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,1,7,2,5 and 1 respectively; the second part has 2 digits, 8 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 917251-86:
(8*9)+(7*1)+(6*7)+(5*2)+(4*5)+(3*1)+(2*8)+(1*6)=176
176 % 10 = 6
So 917251-86-6 is a valid CAS Registry Number.
InChI:InChI=1/C10H5BrF3N/c11-8-3-1-2-6-4-7(10(12,13)14)5-15-9(6)8/h1-5H
917251-86-6Relevant articles and documents
INHIBITORS OF JUN N-TERMINAL KINASE
-
Page/Page column 148, (2010/08/18)
The present disclosure provides inhibitors of c-Jun N-terminal kinases (JNK) having a structure according to the following formula (I): or a salt or solvate thereof, wherein ring A, Ca, Cb, Z, R5, W and Cy are defined herein. The disclosure further provides pharmaceutical compositions including the compounds of the present disclosure and methods of making and using the compounds and compositions of the present disclosure, e.g., in the treatment and prevention of various disorders, such as Alzheimer's disease.
Piperazine-piperidine antagonists and agonists of the 5-HT1A receptor
-
Page/Page column 53, (2010/11/25)
The present invention relates to novel piperazine-piperidine compounds. The compounds are useful as 5-HT1A binding agents, particularly as 5-HT1A receptor antagonists and agonists. These compounds are useful in treating central nervous system disorders, such as cognition disorders, anxiety disorders, depression and sexual dysfunction.
